The Online Investor
Stock Buybacks
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Stock Buybacks

By The Online Investor Staff, updated Sun., May. 31, 9:20 PM

Slide #8. Regeneron Pharmaceuticals, Inc.

Company: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
$Amount Authorized: $5,000,000,000
Buyback Details: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the commencement of an underwritten public secondary offering of its common stock through which Sanofi (NASDAQ: SNY) intends to exit its investment in Regeneron shares. The shares being offered by Sanofi will be sold in an underwritten public offering. Sanofi currently owns approximately 23.2 million Regeneron shares and intends to sell approximately 12.8 million shares in the public offering.1 Sanofi also expects to grant the underwriters a 30-day option to purchase an additional 10% of the shares offered in the base offering. The registered offering and share repurchase will have no impact on the ongoing collaboration between Regeneron and Sanofi. Regeneron also announced today that subject to and immediately following the close of the secondary offering, Regeneron agreed to repurchase approximately $5 billion of common stock directly from Sanofi. The purchase price to be paid by Regeneron will be equal to the net offering price per share after deducting any underwriters' discount and commission. Regeneron will fund the purchase with a combination of $3.5 billion of cash on hand and $1.5 billion of fully-committed bridge financing from Goldman Sachs Bank USA.

Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of diseases. Co.'s commercialized medicines and product candidates in development are designed to assist patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and rare diseases. Co.'s products include: EYLEA (aflibercept) injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema; and Dupixent (dupilumab) injection, which is used for the treatment of adult patients with atopic dermatitis.

Regeneron Pharmaceuticals SEC Filing Email Alerts Service

Open the REGN Page at The Online Investor »

Company Name:  Regeneron Pharmaceuticals, Inc.
Stock buyback:  REGN buyback
Website:  www.regeneron.com
Sector:  Biotechnology
Number of ETFs Holding REGN:  100
Total Market Value Held by ETFs:  $6.54B
Total Market Capitalization:  $60.21B
% of Market Cap. Held by ETFs:  10.87%
 

Open the REGN Page at The Online Investor (in a new window) »

May 31, 2020    9:20 PM Eastern
Quotes delayed 20 minutes



Buy (3.05 out of 4)
45th percentile
(ranked lower than approx. 55% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Stock Buybacks | www.TheOnlineInvestor.com | Copyright © 1998 - 2020, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.